23 research outputs found
Secretin receptor tyrosine phosphorylation site mutation decreases receptor internalization
No full textIncidence of pneumonia and other respiratory tract infections with vedolizumab treatment: clinical trial experience
No full textIncidence of pneumonia and other respiratory tract infections with vedolizumab treatment for inflammatory bowel disease: clinical trial experience
No full textVedolizumab (VDZ) is a humanised monoclonal antibody that binds to α4β7 integrin and selectively blocks gut-specific lymphocyte trafficking. Although upper respiratory tract infections (URTIs) have been reported with VDZ [1] its gut selectivity may reduce the risk of respiratory tract infections (RTIs), including pneumonia, compared with therapies producing systemic immunosuppression (e.g. anti-tumour necrosis factor-alpha [TNFα] agents). We aimed to determine the incidence of RTIs associated with VDZ treatment in the clinical trial setting
Incidence of pneumonia and other respiratory tract infections with vedolizumab treatment for inflammatory bowel disease: clinical trial experience
No full textVedolizumab (VDZ) is a humanised monoclonal antibody that binds to α4β7 integrin and selectively blocks gut-specific lymphocyte trafficking. Although upper respiratory tract infections (URTIs) have been reported with VDZ [1] its gut selectivity may reduce the risk of respiratory tract infections (RTIs), including pneumonia, compared with therapies producing systemic immunosuppression (e.g. anti-tumour necrosis factor-alpha [TNFα] agents). We aimed to determine the incidence of RTIs associated with VDZ treatment in the clinical trial setting
Incidence of pneumonia and other respiratory tract infections with vedolizumab treatment: clinical trial experience
No full textVedolizumab (VDZ) is a humanised monoclonal antibody that binds to α4β7 integrin and selectively blocks gut-specific lymphocyte trafficking. Although upper respiratory tract infections (URTIs) have been reported with VDZ [1] its gut selectivity may reduce the risk of respiratory tract infections (RTIs), including pneumonia, compared with therapies producing systemic immunosuppression (e.g. anti-tumour necrosis factor-alpha [TNFα] agents). We aimed to determine the incidence of RTIs associated with VDZ treatment in the clinical trial setting
G protein-coupled receptor kinase (GRK) specificity of endogenous type 1 vasoactive intestinal polvpeptide (VIP) receptor expressed on the surface of HEK 293 cells
No full textThe role of protein kinase a (PKA) dependent phosphorylation of the secretin receptor in receptor internalization
No full text
